...-infective therapy, the patient received oral osimertinib anti-tumor therapy simultaneously. The tumor receded, but eventually irreversible thrombocytopenia developed. Conclusion: For patients with severe lung cancer, anti-tumor efficacy and adverse events should be closely observed during anti-tumor therapy...

... of NSCLC management. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that has activity against exon 19, exon 21 (L858R) mutations. It is also active against T790M mutation which is the most common resistant mechanism to earlier generation TKIs. Activity of osimertinib against rare EGFR...

... for the epidermal growth factor receptor gene mutation exon 21 L858R and had been treated with osimertinib. She presented with multiple bilaterally positioned thin-walled lung cysts and pneumothorax. Lung cysts were diagnosed as cystic lung metastases from lung cancer, and carboplatin, pemetrexed, and pembrolizumab...

...Zentaro Saito; Takuma Imakita; Takanori Ito; Issei Oi; Osamu Kanai; Kohei Fujita; Hiromasa Tachibana; Tadashi Mio Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor...

... adenocarcinoma, possible primary lung adenocarcinoma of unspecified mutational status in the contralateral lung, and a solitary metastatic lesion in the brain from one of her primary cancers. She was treated with stereotactic radiosurgery and osimertinib in combination with carboplatin/nab-paclitaxel...

...Keisuke Tabata; Masaya Aoki; Ryo Miyata; Tadashi Umehara; Aya Harada-Takeda; Go Kamimura; Toshiyuki Nagata; Ryuya Okizono; Hideyuki Terazono; Yasuo Takeda; Takayuki Suetsugu; Kazuhiro Ueda; Masami Sato Although osimertinib is a key drug in the treatment of non-small cell lung cancer (NSCLC...

... in the right 8th rib. Due to positive mutation of epidermal growth factor receptor (EGFR) exon 21 L858R in the primary cancer, the patient received osimertinib monotherapy, leading to massive calcification of the osteolytic bone metastasis with significant decrease of standard uptake value on positron emission...

... adenocarcinoma, who subsequently developed HCC and squamous cell carcinoma of the femur despite first-line treatment with EGFR-blocking osimertinib. Caris molecular profiling unexpectedly identified a shared underlying VHL mutation in all 3 lesions. Genetic mapping through a machine learning-based tool called...

... mutation treated with a combination of TKIs: osimertinib and ceritinib. [email protected] 30 03 2021 1 04 2021 8 7 2021 © 2021 The Author(s). Published by S. Karger AG, Basel 2021 Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative...

...Turab Mohammed; Shaunak Mangeshkar; Joerg Rathmann Drug-induced interstitial lung disease (DI-ILD) is a rare, yet life-threatening complication associated with tyrosine-kinase inhibitor (TKI) therapy. Third-generation epidermal growth factor receptor-TKI, osimertinib use can be associated...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. T790M mutation Tissue biopsy Liquid biopsy Osimertinib...

... specimen confirmed the diagnosis of lung adenocarcinoma with pleural dissemination and revealed EGFR exon 20-T790M mutation. EGFR-mutated non-small cell lung cancer Osimertinib Rebiopsy T790M Thoracoscopy Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improved...

...-generation EGFR-tyrosine kinase inhibitors (TKIs). Osimertinib is a specific EGFR-TKI to overcome T790M resistance mutation. However, owing to a new drug and a rare mutation type, it remains unknown whether osimertinib is effective for acquired S768I. Herein, we reported a 76 year-old woman with pulmonary...

... mutation (exon 19 deletion and T790M) that acquired resistance to osimertinib treatment because of transformation into small-cell lung carcinoma (SCLC). A 67-year-old ex-smoking woman was diagnosed with left upper lobe adenocarcinoma of clinical stage IIIA (cT2bN2M0). She was treated with chemoradiotherapy...